Expected slowdown given saturation levels in US market and customers awaiting the new product release. Couple this with the recall and increased competition in the sector and the picture as to the price action becomes clear.
That said this is a long term stock. That means 5-10 years.
Just a few points in COH's favour
- It still has 60% of the market
- The new product is slated to be superior to any on the market currently
- COH is still outspending it's rivals on R&D.
The last point is the most important. In companies such as these it's the R&D spend that leads to superior product creation, which in turn makes you the market leader.
Unless the competition or an individual working for them can go from A to C and create a superior product with less R&D spend in the LONG TERM COH is still in the box seat.
News: Cochlear sales slow , page-20
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add COH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$287.89 |
Change
-0.420(0.15%) |
Mkt cap ! $18.81B | |||
| Open | High | Low | Value | Volume |
| $287.00 | $288.94 | $285.68 | $3.584M | 12.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 66 | $287.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $287.89 | 1 | 1 |
View Market Depth
| Last trade - 11.14am 05/11/2024 (20 minute delay) ? |
| COH (ASX) Chart |